EML for Hospitals 2007

THE ESSENTIAL MEDICINES LIST

Government of NCT of Delhi
2007

* For restricted use only 1

 EML for Hospitals 2007

Committee for Selection of Essential Drugs for Hospitals under Government of

NCT of Delhi
1. Prof. R.Roy Chaudhury, Adviser
Advisor to Minister, Health & Family Welfare, Govt. of
NCT of Delhi, Y-85 Hauz Khas, New Delhi.
2. Dr. Usha Gupta Chairperson
Former Professor & Head, Department of Pharmacology,
Maulana Azad Medical College, New Delhi.
3. Dr. Sangeeta Sharma, Professor & Head Member –
Department of Neuropsycho-pharmacology, IHBAS, Delhi. Secretary
4. Dr. M Venkateshwarlu Member
Drugs Controller General of India
Govt. of India, Nirman Bhawan, New Delhi.
5. Dr. B.K. Jain Member
Professor & Head of Surgery
GTB Hospital, Shahdara, Delhi.
6. Dr. P. Bhalla Member
Director Prof. & Head of Microbiology, Maulana Azad
medical College, New Delhi.
7. The Drugs Controller, Member
Swasthya Sewa Nideshalaya Bhawan,
F-17, Karkar Dooma, NCT of Delhi, Delhi.
8. Dr. J.S. Guleria, Member
Former Dean & Head of Medicine,
AIIMS, K-11, Green Park Extn., New Delhi.
9. Dr.J. Devi Member
Director of Health Services
Swasthya Sewa Nideshalaya Bhawan, F-17, Karkar Dooma,
NCT of Delhi, Delhi.
10. Dr. AP Dubey Member
Director Prof. & Head of Pediatrics, LN Hospital, New Delhi.
11. Dr. Richa Dewan Member
Director Prof. & Head of Medicine, LN Hospital, New Delhi.
12. Dr. S.K. Sarin Member
Prof. & Head of Gastroenterology
GB Pant Hospital, New Delhi.
13 Dr. S. Dwivedi Member
Director Professor & Head of Medicine,
GTB Hospital, Shahdara, Delhi.
14 Dr. V.P. Gupta Member
Professor & Head of Opthalmology
GTB Hospital, Shahdara, Delhi.
15 Dr. P.K. Pathak Member
Head of Medicine, DDU Hospital,
Hari Nagar, New Delhi.
16 Prof. S. Batra Member
Director Professor & Head, Department of Obst. & Gynae,
LN Hospital, New Delhi.
17 Prof. KK Aggarwal, Former Medical Superintendent, LN Member
Hospital, New Delhi

* For restricted use only 2

 EML for Hospitals 2007

Contents

Foreword
Preface
The concept of essential medicines
Introduction to Essential Medicines List for Hospitals
Abbreviations
List of drugs added and deleted
Essential Medicines List for Hospitals
Index

* For restricted use only 3

 EML for Hospitals 2007

THE CONCEPT OF ESSENTIAL MEDICINES

Essential medicines are those that satisfy the priority health care needs of the population.
They are selected with due regard to public health relevance, evidence on efficacy and
safety, and comparative cost-effectiveness. Essential medicines are intended to be
available within the context of functioning health systems at all times in adequate
amounts, in the appropriate dosage forms, with assured quality and adequate
information, and at a price the individual and the community can afford. The
implementation of the concept of essential medicines is intended to be flexible and
adaptable to many different situations. Careful selection of a limited range of essential
medicines results in a higher quality of care, better management of medicines (including
improved quality of prescribed medicines) and more cost-effective use of health
resources.

The list of essential medicines relate closely to guidelines for clinical health care
practice, which are used for the training and supervision of health professionals. Lists of
essential medicines also guide the procurement and supply of medicines in the public
sector, schemes that reimburse medicine costs, medicine donations, and local medicine
production.

The Essential Medicines List aims to identify cost-effective medicines for priority
conditions, together with the reasons for their inclusion, linked to evidence-based
clinical guidelines and with special emphasis on public health aspects and considerations
of value of money.

The core list presents a list of minimum medicine needs for a basic health care system,
listing the most efficacious, safe and cost-effective medicines for priority conditions.
Priority conditions are selected on the basis of current and estimated future public health
relevance, and potential for safe and cost-effective treatment.

The complementary list presents essential medicines for priority diseases, for which
specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or
specialist training are needed. In case of doubt medicines may also be listed as
complementary on the basis of consistent higher costs or less attractive cost-
effectiveness in a variety of settings.

Procedure for Revision

This list is a dynamic list and revised every two years. The procedures for updating the
List are in line with the WHO recommended process for developing clinical practice
guidelines. Key components are a systematic approach to collecting and reviewing
evidence and a transparent development process with several rounds of review.

Selection Criteria
The choice of essential medicines depends on several factors, including the public health
relevance and sound and adequate data on the efficacy, safety and comparative cost-
effectiveness of available treatments. Stability in various conditions, the need for

* For restricted use only 4

 EML for Hospitals 2007

special diagnostic or treatment facilities and pharmacokinetic properties are also

considered if appropriate. When adequate scientific evidence is not available on current
treatment of a priority disease, the Expert Committee may either defer the issue until
more evidence becomes available, or choose to make recommendations based on expert
opinion and experience.

Most essential medicines should be formulated as single compounds. Fixed-ratio

combination products are selected only when the combination has a proven advantage in
therapeutic effect, safety or compliance over single compounds administered separately.

In cost comparisons between medicines, the cost of the total treatment, and not only the
unit cost of the medicine, is considered. Cost and cost-effectiveness comparisons may
be made among alternative treatments within the same therapeutic group, but generally
not be made across therapeutic categories (for example, between treatment of
tuberculosis and treatment of malaria). The absolute cost of the treatment will not
constitute a reason to exclude a medicine from the List that other wise meets the stated
selected criteria. The patent status of a medicine is not considered in selecting
medicines for the List.

Other factors which are also considered factors such as local demography and pattern of
disease, treatment facilities, training and experience of the available personnel, local
availability of individual pharmaceutical products, financial resources, and
environmental factors.

Quality of products
Priority is given to ensuring that available medicines have been made according to good
manufacturing practices and are of assured quality. Factors that are to be considered
are:
• Knowledge of, and confidence in the origin of the product;
• The pharmaceutical stability of the product, particularly in the environment that
it will be used;
• Where relevant, bioavailability and bioequivalence information

It is recommended that medicines be purchased from known manufacturers, their duly

accredited agents or recognized international agencies known to apply high standards in
selecting their suppliers.

Promoting rational use

The selection of essential medicines is only one step to improve the quality of health
care. It should be followed by the appropriate use of the selected medicines. Each
individual should receive the right medicine, in an adequate dose for an adequate
duration, with appropriate information, planning of treatment follow up, and at an
affordable cost. In each country and setting, this is influenced by a number of factors,
such as regulatory decisions, procurement, information, training, and the context where
medicines are prescribed or recommended.

* For restricted use only 5

 EML for Hospitals 2007

Training education and the provision of medicines information

For the safe, effective and prudent use of essential medicines, relevant, reliable and
independent medicines information should be available. Health care professionals
should receive education about the use of medicines not only during their training but
also throughout their careers. More highly trained individuals should be encouraged to
assume a responsibility to educate those with less training. Health care providers and
those responsible for dispensing medicines should take every opportunity to inform
consumers about the rational use of these products, including those for self-medication,
at the time they are dispensed.

Governments, universities and professional associations have a major responsibility to

collaborate on improving undergraduate, postgraduate and continuing education in
clinical pharmacology, therapeutics and medicines information issues. Problem-based
pharmacotherapy teaching has been shown to be an effective strategy in this area.

Appropriate medicines information that is well presented ensures that medicines are
used properly and decreases inappropriate medicine use. Ministries of health must take
the responsibility for arranging for the provision of such information. Independent
medicine information activities should be properly funded and if necessary financed
through health care budgets. Electronic, readily accessible sources of medicines
information are becoming available in many settings and can be the basis of reliable
medicines information systems.

Standard clinical guidelines

Standard clinical guidelines are an effective tool for assisting health professionals to
choose the most appropriate medicine for a given condition. These should be developed
and updated on a regular basis. It is not sufficient to develop standard clinical
guidelines without an education and training program to encourage their use.

Drugs and Therapeutic Committees

Drugs and Therapeutic Committees should play an important role in helping to develop
and implement an effective essential medicines program. These committees should be
encouraged to select products for local use from a national essential medicines list, to
measure and monitor the use of medicines in their own environments and undertake
interventions to improve medicines use. There is good evidence that involving Drugs
and Therapeutic Committees and prescribers in guideline development can contribute to
improving prescribing behaviour.

Measuring and monitoring use

Drugs utilization studies are those dealing with the development, regulation, marketing,
distribution, prescription, dispensing, and use of medicines in a society, with special
emphasis on the resulting medical, social and economic consequences. These studies
can examine any level of therapeutic chain, from medicines development to their actual
use by people. They can provide consumption indicators in a given country, area of
institution. Consumption can be quantified as economic expenditure (either in absolute

* For restricted use only 6

 EML for Hospitals 2007

terms or as percentage of total health budget), as number of units, or as defined daily

doses. They can aim at describing the consumption of all medicines, or of particular
groups of medicines or therapeutic areas. Drug utilization studies can be medicine-
oriented (on the use of a particular medicine or group of medicines), or problem-
oriented (on the treatment of a particular condition or disease).

The efficacy of a medicine is most reliably defined on the basis of randomized clinical
trials, which, if well conducted, provide the most reliable estimates of the treatment
effect of a new medicine. Clinical trials cannot be conducted in all possible populations
or settings and their results should therefore be carefully translated into routine clinical
practice. Drug utilization studies aim at providing evidence on the use and the effects of
medicines in routine conditions, and they thus can provide additional evidence of the
evaluation of effectiveness.

Such studies are important tools for identifying those factors or elements of the
therapeutic chain in need of improvement or change. The results should be taken into
consideration when taking regulatory action, selecting medicines, information, training,
and teaching, Institutional and local drug and therapeutic committees should set up drug
utilization studies and other methods for the surveillance of the use of medicines and of
its effects.

* For restricted use only 7

 EML for Hospitals 2007

Essential Medicines List for Hospitals in NCT of Delhi (2006)

The core list presents a list of minimum medicines needs for a basic health care system,
listing the most efficacious, safe and cost-effective medicines for priority conditions.
Priority conditions are selected on the basis of current and estimated future public health
relevance, and potential for safe and cost-effective treatment.

The medicines meant for out-patient and in-patient department are demarcated
separately. The drugs selected for outpatients would also be available to inpatients
department.

The complementary medicines denoted by asterisk (* & ♣) presents essential medicines

for priority diseases, which are expensive and for which specialized diagnostic or
monitoring facilities, and/or specialist medical care, and/or specialist training are
needed. Drugs marked (* & ♣) may be procured in small quantities and their
prescriptions may be monitored.

Each hospital should work out its own mechanism for restrictive use of these drugs to
control costs and to avoid development of resistance to antimicrobials.

NOTE: All paediatric oral formulations should be supplied with an adequate sized
measuring cap transparent with markings shown clearly on the outer side of the
cap.

* For restricted use only 8

 EML for Hospitals 2007

ABBREVIATIONS

Amp. Ampoule
Cap. Capsule
CAPD Continuous ambulatory peritoneal dialysis
Inhal. Inhalation
MDI Metered dose inhaler
Inj. Injection
Amp Ampoule
Linct. Linctus
Oint. Ointment
PDC Peritoneal dialysis concentrate
Susp. Suspension
Syr. Syrup
Liq. Liquid
Tab. Tablet
CR Controlled release
SR Slow release

* For restricted use only 9

 EML for Hospitals 2007

ESSENTIAL DRUGS LIST FOR HOSPITALS

GOVERNMENT OF NCT OF DELHI –2007

List of Drugs added:

Ioversol X-ray contrast media 240mg, 300mg, 320mg, 350mg of iodine/ml in 5ml, 10ml,
20ml vial
Iohexol X-ray contrast media 240mg, 300mg, 350mg/ml in 10ml, 20ml, 50ml
Meropenem Powder for Inj 500mg, 1g
Human albumin 25% in 50ml
GCSF powder for inj 300mcg or 30 MU as active ingredient in 1ml vial
Penta Starch 10%
Enteral nutrition granular form –200g, 400g
Polyclonal Human Anti RhD immunoglobulin 300 mcg
Inj Trypan Blue 0.08%, 0.1% 2ml vial
Inj, Typhoid (Vi antigen) vaccine 30mcg of inactivated Vi capsular polysaccharide/dose vial
Tab. Zolpidem 5mg
Tab. Donepezil 5mg

List of dosage forms added

Acetylsalicylic acid Tab 75mg
Inj Fluroscein sodium 20% 2.5 ml amp
Inj Enoxaparin 60mg/0.6ml pre-filled syringe
Inj Dalteparin 7500IU pre-filled syringe
Self collapsible closed system PVC bag with tamper proof recessible silicon membrane
infusion port with extra self sealing medication port 100ml and 500ml packs of normal
saline, Ringer’s lactate, Dextrose with saline, Dextrose
Ethyl alcohol (70-80%).
Vitamin A Cap 25000IU
List of drugs deleted:
Inj Hydrocortisone acetate 25mg/ml
Inj Dimercaprol 50mg/ml
Inj Disodium calcium Edetate 200mg/ml
Iodine liquid 8mg/5ml
Ethyl chloride spray
Nystatin Ointment1Lac IU/g
Silver nitrate sol. 1 %
Salicylic acid oint.12.5%
Carbolic acid 0.2%, 0.5%
Acriflavin Glycerin sol.0.1 %
Tab Vitamin B1 100mg
GMCSF powder for Inj 150mcg/ml
Monoclonal Anti RhD immunoglobulin 300 mcg

List of dosage forms deleted

* For restricted use only 10

 EML for Hospitals 2007

Acetylsalicylic acid Tab 350mg

Inj Fluroscein sodium 10% 5 ml amp
Inj Enoxaparin 10mg/0.1ml

List of dosage forms with revised specifications

Multivitamin drops (Vitamin A 3000-5000 IU; Vitamin C 40-60 mg ; Vitamin D 400
IU ; Vitamin B1 1-2 mg ; Vitamin B2 1-2 mg ; Vitamin B3 10-15mg; Nicotinamide 10.5
-15mg ; Panthenol 1.5-3mg ; Vitamin B6 1-3 mg ; Vitamin E 5.25- 8mg)

Norfloxacin Tab. 100mg dispersible, 200mg, 400mg coated Tab

Inj Methyl Prednisolone 125mg, 500mg with diluent or separate diluent
Syp Phenobarbitone 20mg/5 ml
Inj Sodium bicarbonate 7.5% isotonic 10 ml ampoule
Inj Pilocarpine 0.5%/1ml preservative free for intraocular use
Sterile Balanced salt sol for anterior chamber irrigation 60ml, 500ml bottle
Sterile Balanced salt sol plus for anterior chamber irrigation 60ml, 500ml bottle
Charcoal tab
Coal tar cream (1-6%)
Boric acid powder
Sol Icthymol 0.15%
Bismuth Iodoform powder
Inj PGF 2alpha as tromethamine 250mcg/ml amp
Inj Sodium Stibogluconate
Surgical spirit 90%
Calcium carbonate with 250mg and 500mg as elemental calcium
Phenytoin susp 30mg/5ml
Tab Primaquin 7.5mg, 15mg
Dicylomine + activated dimethicone/simethicone
Mag hydroxide +_ Alum hydroxide + activated Dimethicone/simethicone Tab, gel,
5-amino-salicylic acid Tab 400 mg enteric coated
Indomethacin Cap Modified release*
* Including Sustained release; controlled release; Timed release and retard preparations
as a foot note
Sod. Diatriazoate (60%) & meglumine diatrizoate (58%)
Calcium carbonate Tab 250mg, 500mg elemental calcium
Inj. Dextrose with saline 5%+0.22% 500ml pack
Dextan 40 (IP) (10% w/v) in NaCl (0.9%w/v)
Thyroxin Tab
Vecuronium Powder for injection 4mg/2 ml amp; 10mg/vial
Carbamazepine Tab 100mg; 200mg
Methyl-prednisolone inj 125mg, 500mg/vial
Chick embryo/Verocel/Human Diploid inj IM/ID pack
Fluconazole Tab/cap 150mg, 200mg
Cytarabine Powder for Inj 100mg amp/vial
Phenytoin sodium inj. 50mg/ml in 2ml amp
Lamotrigine Dispersible Tab/Tab 25mg, 100mg

* For restricted use only 11

 EML for Hospitals 2007

L-asparaginase lyophilized powder for inj 10000KU/vial

Ondansetron inj 2mg/ml 2 ml; 2mg/ml 4 ml

* For restricted use only 12

 EML for Hospitals 2007

ESSENTIAL MEDICINES LIST FOR HOSPITALS

GOVERNMENT OF NCT OF DELHI –2007
OUT-PATIENT IN-PATIENT
1. ANAESTHETICS
GENERAL ANAESTHETICS
Sodium thiopentone Inj.0.5, 1 g Powder/vial
Halothane Inhal.
* Propofol Inj. 1% (50ml/vial)
Nitrous oxide Inhal.
Oxygen Inhal.
*Isoflurane Inhal.
Ketamine hydrochloride Inj.50 mg/ml
Fentanyl Inj.0.05 mg/ml vial
LOCAL ANAESTHETICS
Bupivacaine Hydrochloride
Inj. 0.25%, 0.5% in vial;
Heavy 0.5%
Lignocaine Hydrochloride Inj. 2%; Inj. 5% (with
dextrose 75 mg/ml)
Jelly 2%; Oint. 5%
Spray 10%; Viscous
solution; Topical 4%
Lignocaine with adrenaline Inj. 2% with 5mcg/ml
adrenaline
Inj. 2% with adrenaline
(1:80,000)
PRE-OPERATIVE MEDICATION AND SEDATION FOR SHORT TERM PROCEDURES
Atropine sulphate Inj. 0.6mg/ml
Promethazine Syr/elixir. 5mg/5ml Promethazine hydrochloride Inj. 25mg/ml in 1ml amp
hydrochloride
Diazepam. Tab. 5 mg Diazepam Inj. 5mg/ml
Midazolam Inj. 1mg/ml
Glycopyrrolate Inj. 0.2mg/ml
Triclofos sodium Syr.500mg/5ml in 50ml
2. ANALGESICS, ANTIPYRETICS AND DRUGS FOR GOUT
Acetyl salicylic Acid Tab.75, 100, 150, 325 Pentazocin Lactate Inj. 30mg/ml
mg plain/dispersible
Allopurinol Tab.100 mg *Morphine sulphate Inj. 10 mg/ml

* For restricted use only 13

 EML for Hospitals 2007

*Pethidine Hydrochloride Inj. 50mg/ml

Nimesulide Tab. 100 mg. *Buprenorphine Tab. 0.2mg sublingual
Paracetamol Tab. 500mg Paracetamol Inj. 150mg/ml
Syr. 125mg/5ml
Ibuprofen Tab. 200, 400 mg *Tramadol Cap.50 mg, Inj. 50mg/ml;
Susp. 100mg/5ml 100mg/ml in 2 ml
Indomethacin Cap. 75mg modified
release**
Diclofenac Sodium
Tab. 50 mg Diclofenac sodium Inj. 25mg/ml
Tab. 75 mg SR
Gel 1% w/v 20g
DRUGS FOR MIGRAINE
Dihydroergotamine Tab 1mg
**Modified release includes slow release, sustained release, timed release,
controlled release, retard preparation

3. ANTIALLERGIC AND DRUGS USED IN ANAPHYLAXIS

Chlorpheniramine Tab. 4mg Dexamethasone Sodium Tab. 0.5mg
Maleate phosphate Inj. 4mg/ml
Prednisolone Tab. 5mg Hydrocortisone Sodium Powder for Inj. 100mg/ml
Syr. 5 mg/5ml succinate
Pheniramine maleate Inj. 22.75 mg/ml

Pheniramine maleate Tab. 25, 50 mg Epinephrine Hydrochloride Inj. 1mg/ml

Syr. 15mg/5ml
Cinnarizine Tab. 25 mg
Cetirizine Tab. 10 mg
Syr. 5 mg/5ml
Promethazine Syr/elixir. 5mg/5ml
hydrochloride
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING
Charcoal Tab.
*PAM Inj. 25 mg/ml
Naloxone hydrochloride Inj. 400mcg/ml in 1ml
amp.
D-Penicillamine Cap/Tab.. 250 mg
Anti snake venom (Polyvalent) Inj. Lyophilized
*Methylene blue Inj. 10 mg/ml in 10ml
amp.
Desferrioxamine Powder for Inj.
500 mg in vial
5. ANTI – EPILEPTIC DRUGS
Phenytoin sodium Tab. 50, 100 mg Phenytoin Sodium 50mg/ml in 2ml amp

* For restricted use only 14

 EML for Hospitals 2007

Susp. 30mg/5 ml
Phenobarbitone Syr. 20 mg/5 ml Phenobarbitone Inj. 200 mg/ml
Tab. 30, 60 mg
Carbamazepine Tab. 100 mg,200 mg
*Tab 200 CR, 400 mg CR
Syr. 100 mg/5 ml
Sodium valproate Tab.200mg (enteric coated), Sodium valproate Inj. 100mg/ml
Tab.*200mg CR; 500 mg
CR; Syr. 200mg/5 ml
*Clonazepam Tab. 0.5, 2 mg
*Lamotrigine Tab/dispersible tab.25, 50
mg
6. ANTI – INFECTIVE DRUGS
INTESTINAL ANTHELMINTICS
Mebendazole Tab. 100 mg
Powder for Susp.
100 mg./5 ml
Albendazole Tab. 400 mg
Susp. 200 mg/5 ml
Pyrantel pamoate Tab. 200, 250 mg
Powder for Susp.
50 mg/ml
ANTIFILARIALS
Diethylcarbamazine Tab. 50 mg
dihydrogen citrate
ANTILEISHMANIASIS Sodium stibogluconate Inj. 100 mg/ml
ANTIBACTERIALS
Benzathine Penicillin Powder for Inj. Crystalline penicillin Powder for Inj.0.5
1.2, 2.4 MU/vial MU/vial
Amoxicillin Cap.250, 500 mg Procaine Penicillin G Powder for Inj.
Susp. 125 mg/5 ml 0.4MU/vial
Ampicillin Cap.250, 500 mg Ampicillin Powder for Inj.
Powder for Susp. 500mg/vial
125 mg/5 ml
Cloxacillin Cap.250, 500 mg Cloxacillin Powder for Inj.
Powder for Susp. 500mg/vial
125 mg/5ml
Ciprofloxacin Tab. 250, 500mg Ciprofloxacin Infusion 100 mg/50 ml
Norfloxacin Tab.100 mg dispersible, Chloramphenicol Cap.250 mg
Tab. 200, 400mg Oral Susp. 125 mg/5 ml
Coated Powder for Inj. 1 g/vial
*Ofloxacin Tab.200 mg, 400 mg *Cephalexin Cap.125, 250, 500 mg
Syr. 125 mg/5 ml
Nalidixic acid Tab. 500 mg *Ceftriaxone Powder for Inj.
Syr.300 mg./5 ml 500mg,1g
Erythromycin (as Stearate) Tab.250 mg *Ceftazidime Powder for Inj.250 mg,
Powder for 500 mg, 1g

* For restricted use only 15

 EML for Hospitals 2007

Susp.125mg/5 ml
Roxithromycin Tab. 50, 150mg *Cefuroxime acetil Powder for Inj. 750 mg,
1.5 g vials
Tab. 250 mg; Susp. 125
mg/5 ml
♣
Tab.400 mg+80 mg Piperacillin Powder for Inj. 2g, 4g
Sulfamethoxazole + Tab.800 mg+160 mg
vial
Trimethoprim Oral Susp.200 mg+40
mg in 5 ml
Tab. 100 mg + 20 mg
♣
Doxycycline Cap.100 mg Meropenem Powder for Inj 500mg,
1g vial
Tetracycline Cap.250, 500 mg Gentamicin Inj. 40mg/ml
♣
Amikacin Inj. 100,250,
500mg/2ml
♣
Teicoplanin Inj.200, 400mg/vial
♣
Vancomycin Powder for Inj. 250,
500 mg (as HCl) vial
*Restricted indications only when there is significant resistance to other drugs on the list viz. surgical
prophylaxis in major surgery with implant, severe respiratory infection, and severe skin & soft tissue
infection.
♣
Reserve antimicrobial to be used only when there is significant resistance to other drugs on the list.
ANTILEPROSY DRUGS
Medicines used in the treatment of leprosy should be used only in combination (MDT). Combination therapy is essential to
prevent emergence of drug resistance.
Clofazimine Cap.100 mg
Dapsone Tab.50,100 mg
ANTITUBERCULOUS DRUGS
The regimen recommended depends on the patient treatment category. The World Health Organization recommended
regimen for DOTs (Directly Observed Treatment) is short course chemotherapy. The Government of India has adopted this
in the Revised National Tuberculosis Control Programme (RNTCP). Reserve second line drugs for the treatment of multi-
drug resistant tuberculosis (MDR-TB) should be used in specialized centers only.
Ethambutol Tab.400, 800 mg
Isoniazid Tab.100, 300 mg
Isoniazid + B6 Syr. 100 mg+50 mg/5 ml
Rifampicin Cap.150, 300, 450 mg
Syr. 100 mg/5 ml
Streptomycin Inj.0.75 gm/vial
Pyrazinamide Tab.300, 500, 750 mg
Syr. 250 mg/5 ml
COMBIPACK
Rifampicin Tab. 450 mg
Isoniazid Tab. 300 mg
Pyrazinamide Tab.1500 mg

* For restricted use only 16

 EML for Hospitals 2007

Ethambutol Tab. 800 mg

ANTIFUNGAL DRUGS
Griseofulvin Tab.125, 250 mg *Amphotericin B Powder for Inj.50 mg
vial, 100 mg vial
*Fluconazole Cap/Tab. 50, 150, 200 *Fluconazole .Inj. 2mg/ml infusion
mg 100 ml bottle
Susp. 50mg/5ml
ANTI PROTOZOAL DRUGS
Chloroquine Phosphate Tab.250 mg Chloroquine Inj. 64.5 mg/ml in 5
Syr. 50 mg/5 ml Phosphate ml amp.
Quinine sulphate Tab.300 mg
Sulfadoxin + Pyrimethamine Tab.500 mg+25 mg Quinine Inj. 300 mg/ml in 2ml
Dihydrochloride amp
Primaquine Tab. 7.5, 15 mg
Tinidazole Tab. 300, 500mg
Metronidazole Tab.200, 400 mg Metronidazole Inj. 500 mg/100 ml
Susp. 200 mg/5 ml
Diloxanide furoate Tab.500 mg
ANTIVIRAL DRUGS
* Acyclovir
Powder for Inj. 250
mg vial; Tab. 200 mg
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
**Zidovudine (ZDV
Tab. 300mg
or AZT)
Cap. 100mg.250mg
Susp./Syr. 50mg/5ml
**Lamivudine (3TC) Tab. 150 mg
Oral soln. 50mg/5ml
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
**Nevirapine (NVP) Tab. 200 mg
Oral Susp. 50mg/5ml
PROTEASE INHIBITOR
**Indinavir (IDV) Cap. 200, 333,
400mg
Four antiretroviral drugs have been added for the first time. The antiretroviral drugs do not cure the HIV infection.
Antiretroviral drugs only temporarily suppress viral replication and improve symptoms. They have various adverse effects
and patients receiving these drugs require careful monitoring by adequately trained health professionals. For these reasons,
continued rigorous promotion of measures to prevent new infections is essential and the need for this should not be
diminished in any way by the addition of antiretroviral drugs in the Essential Drugs List. Adequate resources and trained
health professionals are a pre-requisites for the introduction of this class of drugs. Effective therapy requires
commencement of three or four drugs simultaneously, and alternative regimens are necessary to meet specific requirements
at start-up, to substitute for first line regimens in case of toxicity, or to replace failing regimens. The committee strongly
recommends to follow treatment guidelines developed by National AIDS Control Organization (NACO). NOTE:
Antiretroviral drugs should be procured from separate budget

* For restricted use only 17

 EML for Hospitals 2007

7. ANTIPARKINSONISM DRUGS
Trihexyphenidyl Tab. 2mg *Bromocriptine Tab 2.5mg
Levodopa + Carbidopa Tab. 100 mg + 10 mg
Tab. 100 mg + 25 mg
Tab. 250 mg + 25 mg
8. DRUGS AFFECTING BLOOD
ANTIANAEMIC DRUGS
Ferrous Sulphate Tab. 200 mg (equivalent to 60 mg
elemental iron)
Ferrous fumarate Drops 5 mg/ml
Folic acid Tab. 5 mg Iron sorbital Citric Inj. 75 mg
acid complex iron/1.5 ml
Iron folic acid Tab Ferrous sulphate
Exsiccated IP 333-335 mg (equivalent
to 100 mg of elemental iron) + folic
acid IP 0.5 mg; Tab. Ferrous sulphate
Exsiccated IP 67 mg (equivalent to 20
mg of elemental iron) + folic acid IP
0.1 mg
DRUGS AFFECTING COAGULATION
Heparin Inj. 1000 IU/ml Vitamin K Inj. 10 mg/ml
Inj. 5000 IU/ml
*Tranexamic acid Tab.250,500 mg Enoxaparin (Pre-Filled Inj. 20mg/0.2 ml; 40
syringes) mg/0.4 ml; Inj.
60mg/0.6ml
Dalteparin (Pre-Filled Inj. 2500IU/0.2ml,
syringes) 5000 IU/0.2 ml;
7500 IU/0.2 ml
Warfarin Tab. 5 mg
*Streptokinase Inj. 15,00,000 IU
Protamine sulphate Inj. 10 mg/ml in 5 ml
ampoule
9. BLOOD PRODUCTS & SUBSTITUTES
Penta Starch Inj.10%
Dextran 40 Inj (Dextran 40
10%w/v) in NaCl
(0.9% w/v); (Dextran
40 10%w/v) in dextrose
(5% w/v);
10. CARDIOVASCULAR DRUGS
ANTIANGINAL DRUGS
Atenolol Tab.50, 100 mg Metoprolol Inj. 1 mg/ml
Tab.50,100 mg
Glyceryl trinitrate Tab.0.5 mg Glyceryl trinitrate Inj. 5 mg/ml

* For restricted use only 18

 EML for Hospitals 2007

Oint. 2% 30 g pack
Isosorbide dinitrate Tab.10, 20 mg
Isosorbide mononitrate Tab. 10, 20 40 mg
ANTIDYSRHYTHMIC DRUGS
Verapamil. Tab.40, 80 mg Diltiazem Tab.30,60 mg
Inj. 5mg/5 ml amp Inj. 25 mg/vial
Adenosine Inj. 3mg/ml in 2 ml
amp
Lignocaine Inj. 2% (21.3 mg/ml)
(preservative free)
Amiodarone Tab.200 mg
Inj. 150 mg/vial (3ml)
ANTIHYPERTENSIVE DRUGS
Amlodipine Tab. 5 mg Sodium nitroprusside Inj. 50 mg/5 ml
Enalapril Tab. 2.5, 5 mg
§
Methyldopa Tab. 250 mg
§
Methyl dopa is listed for use in the management of pregnancy-induced hypertension only. Its use in the treatment of
essential hypertension is not recommended in view of the availability of drugs with better efficacy and safety.
CARDIAC GLYCOSIDES
Digoxin Tab. 0.25 mg Digoxin Inj. 250 mcg/ml in 2ml
Syr. 0.05 mg/ml amp.
HYPOLIPIDAEMIC AGENTS
This class of drugs has been added for the first time. These drugs have been shown to reduce the incidence of fatal and non
fatal myocardial infarction, stroke and mortality (all causes), as well as the need for coronary by-pass surgery. All remain
very costly but may be cost-effective for secondary prevention of cardiovascular disease as well as primary prevention in
some very high-risk patients.
*Fenofibrate Cap. 200mg
*Simvastatin Tab 5, 10, 20mg
DRUGS USED IN VASCULAR SHOCK AND PERIPHERAL VASCULAR DISEASES
*Dobutamine Inj. 50 mg/ml, 5 ml
vial.
*Dopamine Inj. 40 mg/ml, 5 ml
vial.
11. DERMATOLOGICA DRUGS
ANTIFUNGAL DRUGS
Clotrimazole Cream 1% Powder 1%
Vaginal pessary 100 mg
Miconazole nitrate Oint. 2%
Benzoic acid + Oint. (6% + 3%)
Salicylic acid
ANTI – INFECTIVE DRUGS
Silver sulfadiazine Cream 1% in 20g and 100mg
Framycetin Cream 1 % in 20g and 100g pack

* For restricted use only 19

 EML for Hospitals 2007

Povidone iodine Powder 5%; Sol. 5%; Ointment

5%; Vaginal pessary 200 mg
SCABICIDES AND PEDICULOCIDES
Permethrin Lotion1% 60 ml; Cream 5%
ANTI – INFLAMMAORY AND ANTIPRURITIC DRUGS
Betamethasone Cream, Ointment 0.1%
Valerate
Clobetasol Cream, 0.05% in 10 g tube
Calamine Lotion
KERATOPLASTIC AND KERATOLYTIC AGENTS
Coal tar Cream 1-6% Podophyllin Resin 20%
ULTRAVIOLET BLOCKING AGENTS
Trimethyl psoralen Tab. 5 mg, 25 mg
OTHERS
Tretinoin Cream 0.05% in 20 g Triamcinolone Inj. 10mg, 40 mg/ml
amp
Glycolic acid Soln. 70% in 500ml
12. DIAGNOSTIC AGENTS
ORAL CONTRAST AGENTS
Barium sulphate Powder
Susp.95% w/v
Powder (HD) 95% w/w
250% w/v
IONIC INTRA VASCULAR CONTRAST AGENTS
Sodium diatrizoate and Inj. 75% and 76% in
meglumine Diatrizoate 20ml, 50 ml, 100 ml
Inj. 60% and 58% in 20
ml, 50 ml
Meglumine iothalmate Inj. 60% w/v in 30ml
Sodium iothalmate Inj. 66.8% w/v in 50 ml
NON - IONIC INTRA VASCULAR CONTRAST AGENTS
Ioversol Inj 240mg, 300mg,
320mg, 350mg of
Iodine/ml in 20ml,
50ml, 100ml vial
Iohexol Inj 240mg, 300mg,
350mg/ml in 20ml,
50ml, 100ml
13. DISINFECTANTS AND ANTISEPTICS
Chlorhexidine Soln. 0.2% Glutaraldehyde activated Solution 2% w/v
Scrub without foaming to remain
alkaline for 2 weeks

* For restricted use only 20

 EML for Hospitals 2007

Tincture Benzoin Co.

Surgical Spirit Liquid
Ethyl alcohol (70-80%) Liquid
Eusol (chlorinated lime
1.25%+ boric acid 1.25%)
Hydrogen Peroxide Sol.6% w/v
Formaldehyde Sol., Tab.1g
Gentian violet Crystals for sol
Potassium Permanganate Crystals for sol.
14. DIURETICS
Hydrochlorothiazide Tab. 25, 50 mg Mannitol Inj. 20%
Spironolactone Tab. 25, 100 mg Glycerol Syr.
Frusemide Tab. 40 mg Frusemide Inj. 10 mg/ml
15. GASTROINTESTINAL DRUGS
ANTACIDS AND OTHER ANTI-ULCER DRUGS
Magnesium hydroxide + Tab. (250 mg + 250 Omeprazole Cap. 20 mg
aluminium hydroxide + mg + 50 mg)
activated Gel (250 mg + 250 mg
dimethicone/simethicone + 50 mg/5 ml)
Ranitidine Tab. 150 mg Ranitidine Inj. 50 mg/2 ml
PROKINETIC AGENT
Mosapride citrate dehydrate Tab 5 mg
ANTIEMETIC DRUGS
Metoclopromide Tab. 10 mg Metoclopromide Inj. 5 mg/ml amp.
Domperidone Tab. 10 mg *Ondansteron Inj 2mg/ml 2 ml; 2mg/ml
Susp. 1 mg/ml 4 ml
ANTI-HAEMORRHOIDAL DRUGS
Beclomethasone Oint (0.025%, 0.1% +
dipropionate + 2.5%)
Phenylephrine + Lignocaine
ANTIINFLAMMATORY DRUGS
5-Amino salicylic acid Tab. 400 mg enteric
coated
ANTISPASMODIC DRUGS
Dicyclomine Tab. 10 mg Dicyclomine Inj. 10 mg/ml
Dicyclomine + Activated Drops 10 mg+40
dimethicone/simethicone mg/ml
Hyoscine butylbromide Tab. 10 mg Hyoscine butylbromide Inj. 20 mg/ml

* For restricted use only 21

 EML for Hospitals 2007

CATHARTIC DRUGS
Bisacodyl Tab. 5 mg
Lactulose Syr. 667 mg/ml
DRUGS USED IN DIARRHOEA
ORS (Low osmolarity: 245 Powder sachet
mmol/L: Sod chloride
2.6g/L, Trisodium citrate
dehydrate 2.9g/L, Pot.
Chloride 1.5g/L, Glucose
anhydrous 13.5g/L)
Furazolidone Tab. 100 mg
Powder for Susp.
25mg/5ml

16. HORMONES, OTHER ENDOCRINE DRUGS AND CONTRACEPTIVES

PITUITARY HORMONE
*Octreotide 50, 100, 500 mcg/ml in 1ml
Amp.; 200 mcg/ml – 5 ml vial .
ADRENAL HORMONES AND SYNTHETIC SUBSTITUTES
Prednisolone Tab.5, 10, 20 mg Methylprednisolone Inj. 125mg/vial; 500 mg/vial
Liq.5 mg/5ml in with diluent or separate diluent
120 ml bottle
Clomiphene citrate Tab.50mg
ANDROGENS’
Nandrolone Inj.25 mg/ml
decanoate
CONTRACEPTIVES
Ethinyloestradiol Tab.30 mcg+150 mcg; 30
+ Levonorgestrel mcg +250 mcg
OESTROGENS
Ethinyloestradiol Tab.0.01,0.05 mg
Conjugated equine Tab.0.625, 1.25mg
oestrogen

PROGESTERONES
Norethisterone Tab.5 mg
Medroxy Tab.2.5, 10 mg
progesterone acetate
Danazol Tab.200 mg

* For restricted use only 22

 EML for Hospitals 2007

INSULIN AND OTHER ANTIDIABETIC DRUGS

Glibenclamide Tab.2.5, 5 mg *Insulin Soluble Inj.40 IU/ml
(Human) Long
Acting
Metformin Tab.500, 850 mg *Insulin NPH Inj. 40IU/ml
hydrochloride (Human)
∞Insulin Glargine Inj.100 IU/ml cartridge & vial
(Human)
*Insulin Premixed Inj 30%/70% in 40IU/ml,
(Human) 100IU/ml
∞ To be used only in patients with poor glycemic control with other insulins
DRUGS AFFECTING CALCIFICATION AND BONE TURNOVER
*Alendronate Tab 10, 70mg
THYROID HORMONES AND ANTITHTROID DRUGS
Thyroxine sodium Tab.50, 100 mcg
Carbimazole Tab.5mg
17. IMMUNOLOGICAL AGENTS
There should be no batch failure rate/substandard report from the authorized testing laboratory.
Tetanus toxoid Inj. T.I.G. Inj.250 IU
B.C.G. IP (freeze dried) Inj.
D.P.T. IP (adsorbed) Inj. Antidiphtheritic Inj.10000 IU, 20000 IU/amp
Serum
D.T. IP (adsorbed) Inj.
MMR (live vaccine) Inj. USP
Measles IP Inj. 1000 TICD 50
Poliomyelitis IP Oral
Typhoid (Vi antigen) Inj 30mcg
vaccine inactivated Vi
capsular
polysaccharide/dose
vial
Hepatitis B Inj. 20 mcg
Anti rabies vaccine (chick-
Inj. IM/ID pack
Embryo /Verocell/Human
diploid)
*Anti Rh (D) Inj. 300 mcg/1.5ml
Immunoglobulin Polyclonal

Intradermal injection to be administered by skilled personnel

18. MUSCLE RELAXANT & ANTICHOLINESTERASE

* For restricted use only 23

 EML for Hospitals 2007

Neostigmine Tab.15 mg Neostigmine Inj.0.5, 2.5 mg in 1ml

Methocarbamol Tab.500 mg Vecuronium Powder for injection
4mg/2 ml amp; 10mg/vial
Pancuronium Inj. 2mg/ml in 2ml amp.
Atracurium Inj.10 mg/ml in 2.5 ml amp
Succinyl choline Inj. 50 mg/ml

19. OXYTOCICS AND ANTIOXYTOCICS

Isoxsuprine Tab. 10 mg Isoxsuprine Inj. 5 mg/ml
Oxytocin Inj. 5 IU/ml
Methylergometrine maleate Tab. 0.125 mg Methylergometrine Inj.0.2 mg/ml
maleate
Magnesium sulphate Inj. 50% w/v
*Dinoprostone Inj.0.5 mg/syringe
*Ethacridine lactate Inj.1mg/ml
*PGF2α as Inj.250 mcg/ml amp.
tromethamine
20. PERITONEAL DIALYSIS SOLUTIONS
Intraperitoneal 1.5% dextrose, 2.5% dextrose,
dialysis concentrate 4.5% dextrose
21. PSYCOTHERAPEUTIC DRUGS
Imipramine Tab. 25, 75mg
Fluoxetine Cap. 20mg
Amitriptyline Tab. 10,25,75mg
Trifluoperazine Tab. 5mg *Clozapine Tab.25, 100 mg
Chlorpromazine Tab. 25,50, 100mg
Fluphenazine decanoate Inj. 25mg/ml
Risperidone Tab. 2mg
Haloperidol Tab. 5,10mg Haloperidol Inj. 5 mg/ml
Lithium carbonate Tab. 300mg
Diazepam Tab. 5mg
Lorazepam Tab. 1,2mg Lorazepam Inj.2 mg/ml
Alprazolam Tab.0.25mg, 0.5mg
Zolpidem Tab 5mg
Donepezil Tab 5mg

* For restricted use only 24

 EML for Hospitals 2007

22. DRUGS ACTING ON RESIRATORY SYSTEM

Etiophylline+ theophylline Tab.100mg(77+23); Etiophylline+ Inj.220mg/2 ml (169.4+50.6 mg)
Tab. 150, 300mg SR; theophylline
syr.(46.5+14mg/5ml)
Salbutamol Tab. 2, 4mg
Salbutamol Sol for Nebulizer 5 mg/ml;
Syr. 2mg/5ml *Inhalation aerosol 100 mcg/dose in
200 doses

Budesonide Inhalation aerosol 100mcg/dose

Ipratropium Soln. for nebuliser 250mcg/ml in 15
bromide ml vial; *Inhalation aerosol
20mcg/dose
**Surfactant Natural Bovine Lung Surfactant with
solution for added DPCC, tripalmitin and palmitic
intratracheal acid 8 ml vial
instillation
ANTITUSSIVES
Noscapine Linctus 7mg/5 ml
Drops1.83mg/ml
Dextromethorphan Soln.30 mg/5ml
Bromhexine HCl Syr.4mg/5 ml
Diphenhydramine Syr.12.5 mg/5 ml

Metered dose inhalers are for restricted use and should be prescribed in
diagnosed cases of chronic asthma only for prevention and treatment. **to be used
in neonatal ICUs .
23. SOLUTION CORRECTING WATER AND ELECTROLYTE
Dextrose Inj.5%, 10%, 25%, 50%
¥Inj. 100ml and 500ml IV fluid
bag self collapsible closed system
with self sealable medication port
Sodium chloride Inj.0.9% 100ml, 500ml bottle;
¥Inj. 100ml and 500ml IV fluid
bag self collapsible closed system
with self sealable medication port
Ringer’s lactate Inj.
¥Inj. 100ml and 500ml IV fluid
bag self collapsible closed system
with self sealable medication port
Distilled water Inj.
Dextrose with saline Inj. 5% + 0.45%; 5% + 0.9%;
5% + 0.22%
¥Inj. 100ml and 500ml IV fluid
bag self collapsible closed system
with self sealable medication port
Water for injection Inj. 2ml, 5ml, 10ml amp

* For restricted use only 25

 EML for Hospitals 2007

Glycine Inj.1.5%
Potassium chloride Inj.150 mg/ml
Calcium gluconate Inj.10%
Sodium bicarbonate Inj. 7.5% isotonic 10 ml amp
¥ for use in critical care units such as ICUs, post operative and burn wards only
24. VITAMINES AND MINERALS
Vitamin. A Soft gelatin Vitamin. A Inj.1 lac IU/2 ml
Cap.25,000IU,
50,000 IU
Multivitamin (Vit A 3000-5000 Vitamin B1 Inj. 100 mg/ml
IU; Vit C 40-60mg;
Vit D 400 IU; Vit B1
1-2mg; Vit B2 1-
2mg; Vit B3 10-
15mg; Nicotinamide
10.5-15mg;
Panthenol 1.5-3mg;
Vit B6 1-3mg; Vit E
5.25-8mg) Drops
Vitamin D3 Granules 1 g sachet Vitamin B12 Inj. 500 mcg/ml
Alphacalcidol Cap.0.25 mcg Vitamin D3 Inj. 6 lac IU/ml
Vitamin C Tab.100, 500 mg
Pyridoxin Tab.10 mg
Calcium carbonate Tab. 250, 500 mg as
elemental calcium
Calcium carbonate+ Syr. Elemental
Vitamin D3 calcium 250mg +Vit
D3 125 IU/5 ml
25. DENTAL PREPARATIONS
Tannic acid Gum paint10%
Povidone iodine Mouth wash 1 %
Choline Salicylate Gel (0.01% + 9% all
soln + Benzalkonium w/v) 8.7% Soln. IP
chloride soln + 0.01% w/w 2% w/w
Lignocaine HCL IP in flavored jelly base
oral gel 30g/tube

26. OPHTHALMOLOGICAL PREPARATIONS

ANTI-INFECTIVE AGENTS
Sulfacetamide Eye drops 20% *Acyclovir Eye ointment 3%
Ciprofloxacin Eye drops 0.3% *Tobramycin Eye drops 0.3%
Eye oint.0.3%
Chloramphenicol Eye applicap 1% *Natamycin Eye drops 5% in 5ml vial

* For restricted use only 26

 EML for Hospitals 2007

Eye drops 0.5, 1%

Gentamicin Eye drops 0.3%
Framycetin Eye drops 0.5%
ANTIINFLAMMATORY AGENTS
Dexamethasone + Eye drops (0.1% +
Neomycin 0.5%)
Dexamethasone Eye drops 0.1%
Dexamethasone + Eye drops (0.1% +
Gentamicin 0.3%)
Ketorolac Eye drops 0.5%/5ml
vial
MIOTICS AND ANTIGLAUCOMA DRUGS
Pilocarpine Eye drops 2% Pilocarpine Inj.0.5%/1ml amp preservative free
for intraocular use
Timolol Eye drops 0.5%
MYDRIATICS
Homatropine Eye drops 2%
hydrobromide
Tropicamide Eye drops 1%
Phenylephrine Eye drops 10%
Atropine sulphate Eye oint.1%
OTHERS Tryptan Blue 0.08%, 0.1% 2 ml vial
Lubricating eye drops Eye drops Fluoroscein sodium Inj. 20% 2.5 ml amp;
(Polyvinyl alcohol Strips
1.4%+Povidone 0.6%
+ chlorbutanol 0.5%)
Hydroxypropyl Drops 0.7% Hydroxypropyl 2% prefilled syringe
Methylcellulose Methylcellulose
Acetazolamide Tab.250 mg Hyaluronidase Inj.1500 Unit/ml
1 ml vial
Proparacain Eye drops 0.5% in 5ml vial
Balanced salt Sterile Sol. for anterior chamber
irrigation 60ml, 500ml bottle;
Sterile Sol. Plus for anterior chamber
irrigation 60ml, 500ml bottle
27. ANTICANCER DRUGS
Mercaptopurine Tab.50 mg
Leucovorin (calcium) Inj.3 mg/ml
Methotrexate Tab. 2.5 mg
Inj.50 mg/2 ml
Melphalan Tab. 5 mg

* For restricted use only 27

 EML for Hospitals 2007

Tamoxifen Tab.10, 20 mg
Cyclophosphamide Tab. 50 mg
Inj. 200, 500 mg/vial
Procarbazine Cap. 50 mg
Cyclosporine A Cap. 50, 100 mg
Inj. 100 mg/ml
Cytosine arabinoside Inj. 20 mg/ml
Bleomycin Inj. 15 mg/amp.
Cisplatin Inj.0.5 mg/ml
Vincristine Inj. 1 mg amp.
Doxorubicin Inj.10, 50 mg/vial
Etoposide Inj.20 mg/ml
5-Fluorouracil Inj.50 mg/ml
*GCSF Powder for injection (300 mcg/ml or
30 u as active ingredient in 1ml vial)
*L-asparaginase Lyophilized Powder for Inj.10,000
KU/vial
*Daunomycin Inj.20mg/vial
*Paclitaxel Inj.30mg, 100mg, 260mg vial

28. SOLUTIONS FOR ENTERAL and PARENTERAL NUTRITION

Amino acid solution 10% for infusion in 100ml,.200ml,
for parenteral 500ml (containing tryptophan,
nutrition phenylalanine, lysine, threonine, methionine,
leucine, isoleucine and valine)
6% for infusion in 100ml (Containing
Taurine, histidine, tyrosine, cystine, glutamic
acid and aspartic acid & lower amounts of
methionine & phenylalanine in paediatric
formulation)
Fat emulsion for 10% parenteral nutrition in 100, 200,
Infusion 500ml; 6% in 100ml
Human Normal Infusion 25% in 50ml
Serum Albumin

Enteral nutrition Granular form sachets caloric dietary
product 1kcal/ml (protein ~14%cal,
caseinates, soy, lactalbumin; Fat ~
30% cals, corn, soy, safflower oils;
CHO ~60% cals, hydrolysed corn
starch, maltodextrin, sucrose;
recommended daily intake of all
minerals and vitamins in
>1500kcal/d; osmolarity ~300
mosm/kg

For restricted use in post operative patients only

* For restricted use only 28

 EML for Hospitals 2007

29. ENT DRUGS

Gentamicin Ear drops (0.3% w/v) Icthymol Sol. 0.15%
Gentamicin+ Ear drops (0.3% w/v Bismuth lodoform Powder
Betamethasone + 0.1%)
Sodabicarb glycerine Drops 8%
Clotrimazole Ear drops 1%
Xylometazoline Nasal drops 0.1,
0.05%
Glucose in glycerine Drops 25%
Chloramphenicol Ear drops 5%
Boric acid Powder

* For restricted use only 29

 EML for Hospitals 2007

Index

* For restricted use only 30

 EML for dispensaries 2007

A
5-Amino salicylic acid 12
Acetazolamide 13
Acetyl salicylic acid 2
Acyclovir 6,17
Adenosine 8
Albendazole 4
Alendronate 13
Allopurinol 2
Alphacalcidol 17
Alprazolam 15
Amikacin 5
Aminoacid solution for parenteral nutrition 19
Amiodarone 9
Amitriptyline 15
Amlodipine 9
Amoxicillin 4
Amphotericin B 6
Ampicillin 4
Anti rabies vaccine 14
Anti Rh (D) Ig 14
Anti snake venom 3 Antidiphtheritic serum 14
Atenolol 8
Atracurium 15
Atropine sulphate 1,18

B
B.C.G. IP (freeze dried) 14
Balanced salt plus sol. 18
Barium sulphate 10
Beclomethasone dipropionate + Phenylephrine + Lignocaine 12
Benzathine penicillin 4
Benzoic acid + Salicylic acid 9
Betamethasone valerate 10
Bisacodyl 12
Bismuth iodoform paste 19
Bleomycin 18
Boric acid 19
Bromhexine 16
Bromocriptine 7
Budesonide 16
Bupivacaine 1
Buprenorphine 2

C
Calamine 10
Calcium carbonate 17
Calcium carbonate+vitaminD3 17
Calcium gluconate 16

* for restricted use only 1

 EML for dispensaries 2007

Carbamazepine 3
Carbimazole 13
Ceftazidime 4
Ceftriaxone 4
Cefuroxime axetil 5
Cephalexin 4
Cetirizine 2
Charcoal
Chloramphenicol 4,17,19
Chlorhexidine 11
Chloroquine phosphate 6
Chlorpheniramine maleate 2
Chlorpromazine 15
Choline Salicylate soln 17
Cinnarizine 2
Ciprofloxacin 4,17
Cisplatin 18
Clobetasol 10
Clofazimine 5
Clomiphene citrate 13
Clonazepam 3
Clotrimazole 9,19
Cloxacillin 4
Clozapine 15
Coal tar 10
Conjugated equine oestrogen 13
Crystalline penicillin 4
Cyclophosphamide 18
Cyclosporine A 18
Cytosine arabinoside 18

D
D.P.T. IP (adsorbed) 14
D.T. IP (adsorbed) 14
Dalteparin 8
Danazol 13
Dapsone 5
Daunomycin 19
Desferrioxamine 3
Dexamethasone 2,17
Dexamethasone+Gentamicin 17
Dexamethasone+Neomycin 17
Dexamethasone sodium phosphate 2
Dextran 10% in dextrose 5% 16
Dextran 40 8
Dextromethorphan 16
Dextrose 16
Dextrose with saline 16
Diazepam 1,15

* for restricted use only 2

 EML for dispensaries 2007

Diclofenac sodium 2
Dicylomine 12
Diethylcarbamazine dihydrogen citrate 4
Digoxin 9
Dihydroergotamine 2
Diloxanide furoate 6
Diltiazem 8
Dinoprostone 15
Diphenhydramine 16
Distilled water 16
Dobutamine 9
Domperidone 12
Donepezil 13
Dopamine 9
Doxorubicin 18
Doxycycline 5
D-Penicillamine 3

E
Enalapril 9
Enoxaparin 8
Enteral nutrition 17
Epinephrine hydrochloride 2
Erythromycin (as Stearate) 4
Ethacridine lactate 15
Ethambutol 5
Ethinyloestradiol 13
Ethinyloestradiol + Levonorgestrel 13
Etiophylline+ theophylline 15
Etoposide 18
Eusol 11

F
Fat emulsion for infusion 19
Fenofibrate 9
Fentanyl 1
Ferrous fumarate drops 7
Ferrous sulphate 7
Fluconazole 6
Fluorescein 18
5-Fluorouracil 19
Fluoxetine 15
Fluphenazine decanoate 15
Folic acid 7
Formaldehyde 11
Framycetin 9,17
Frusemide 11
Furazolidone 12

* for restricted use only 3

 EML for dispensaries 2007

G
Gentamicin 5,17,19
Gentamicin+Betamethasone 19
Gentian violet 11
Glibenclamide 13
Glucose in glycerine 19
Glutaraldehyde 11
Glycerol 11
Glyceryl trinitrate 8
Glycine 16
Glycolic acid 10
Glycopyrrolate 2
GCSF 19
Griseofulvin 6

H
Haloperidol 15
Halothane 1
Heparin 8
Hepatitis B 14
Homatropine hydrobromide 18
Human albumin 19
Hyaluronidase 18
Hydrochlorothiazide 11
Hydrocortisone sodium
succinate 2
Hydrogen peroxide 11
Hydroxypropyl-Methylcellulose 18
Hyoscine butylbromide 12

I
Ibuprofen 2
Icthymol 19
Imipramine 15
Indinavir (IDV) 7
Indomethacin 2
Insulin glargine (Human) 13
Insulin NPH (Human) 13
Insulin premixed (Human) 13
Insulin soluble (Human) 13
Intraperitoneal dialysis concentrate 15
Iohexol 11
Ioversol 11
Ipratropium bromide 16
Iron folic acid 7
Iron sorbital Citric acid 7
Isoflurane 1
Isoniazid 5
Isoniazid + B6 5

* for restricted use only 4

 EML for dispensaries 2007

Isosorbide dinitrate 8
Isosorbide mononitrate 8
Isoxsuprine 15

K
Ketamine hydrochloride 1
Ketorolac 17

L
Lactulose 12
Lamivudine (3TC) 7
Lamotrigine 3
L-asparaginase 19
Leucovorin (calcium) 18
Levo thyroxine sodium 13
Levodopa + Carbidopa 7
Lignocaine (preservative free) 9
Lignocaine hydrochloride 1,17
Lignocaine with adrenaline 1
Lithium carbonate 15
Lorazepam 15
Lubricating eye drops 18

M
Magnesium hydroxide + aluminium hydroxide 11
Magnesium sulphate 15
Mannitol 11
Measles IP 14
Mebendazole 3
Medroxy progesterone acetate 13
Meglumine iothalmate 10
Melphalan 18
Mercaptopurine 18
Meropenem 5
Metformin hydrochloride 13
Methocarbamol 15
Methotrexate 18
Methyldopa 9
Methylene blue 3
Methylergometrine maleate 15
Methylprednisolone 13
Metoclopromide 12
Metoprolol 8
Metronidazole 6
Miconazole nitrate 9
Midazolam 1
MMR (live vaccine) 14
Morphine sulphate 2
Mosapride 12

* for restricted use only 5

 EML for dispensaries 2007

Multivitamin 17

N
Nalidixic acid 4
Naloxone hydrochloride 3
Nandrolone decanoate 13
Natamycin 17
Neostigmine 15
Nevirapine (NVP) 7
Nimesulide 2
Nitrous oxide 1
Norethisterone 13
Norfloxacin 4
Noscapine 16

O
Octreotide 12
Ofloxacin 4
Omeprazole 11
Ondansteron 12
ORS (WHO) 12
Oxygen 1
Oxytocin 15

P
Paclitaxel 19
PAM 3
Pancuronium 15
Paracetamol 2
Penta starch
Pentazocin lactate 2
Permethrin 10
Pethidine hydrochloride 2
PGF2α 15
Pheniramine maleate 2
Phenobarbitone 3
Phenylephrine 18
Phenytoin sodium 3
Pilocarpine 18
Piperacillin 5
Podophyllin resin 20% 10
Poliomyelitis IP 14
Potassium chloride 16
Potassium permanganate 11
Povidone iodine 9,17
Prednisolone 2,13
Primaquine 6
Procaine penicillin G 4
Procarbazine 18

* for restricted use only 6

 EML for dispensaries 2007

Promethazine 1
Proparacain 18
Propofol 1
Protamine sulphate 8
Pyrantel pamoate 4
Pyrazinamide 6
Pyridoxin 17

Q
Quinine dihydrochloride 6
Quinine sulphate 6

R
Ranitidine 11
Rifampicin 5
Ringer’s lactate 16
Risperidone 15
Roxithromycin 4
S
Salbutamol 16
Silver nitrate 10
Silver sulphadiazine 9
Simvastatin 9
Sodabicarb glycerine 19
Sodium stibo gluconate 4
Sodium bicarbonate 16
Sodium chloride 16
Sodium diatrizoate and meglumine diatrizoate 10
Sodium iothalmate 11
Sodium Nitroprusside 9
Sodium thiopentone 1
Sodium valproate 3
Spirit surgical 11
Spirit (70-80% alcohol) 11
Spironolactone 11
Streptokinase 8
Streptomycin 6
Succinyl choline 15
Sulphacetamide 17
Sulphadoxin + Pyrimethamine 6
Sulphamethoxazole + Trimethoprim 4
Surfactant solution 16

T
T.I.G. 14
Tamoxifen 18
Tannic acid gum paint 17
Teicoplanin 5

* for restricted use only 7

 EML for dispensaries 2007

Tetanus toxoid 14
Tetracycline 5
Timolol 18
Tincture benzoin Co 11
Tinidazole 6
Tobramycin 17
Tramodol 2
Tranexamic acid 8
Tretinoin 10
Triamcinolone 10
Triclofos sodium 2
Trifluoperazine 15
Trihexyphenidyl 7
Trimethyl psoralen 10
Tropicamide 18
Typhoid vaccine 12

V
Vancomycin 5
Vecuronium 15
Verapamil 8
Vincristine 18
Vitamin B1 17
Vitamin B12 17
Vitamin C 17
Vitamin D3 17
Vitamin K 8
Vitamin A 17

W
Warfarin 8
Water for injection 16

X
Xylometazoline 19

Z
Zidovudine (ZDV or AZT) 6 Zolpidem 13

* for restricted use only 8

 EML for dispensaries 2007

LIST OF “ESSENTIAL MEDICINES ” FOR DISPENSARIES AND HEALTH CENTERS

GOVERNMENT OF NCT OF DELHI

1. LOCAL ANAESTHETICS
Lignocaine with adrenaline Inj. 2% with 5mcg/ml adrenaline
2. ANALGESICS, ANTIPYRETICS AND DRUGS FOR GOUT
Acetyl salicylic Acid Tab.75, 100, 150, 325mg plain/soluble
Pentazocin Lactate Inj. 30mg/ml
Nimesulide Tab. 100 mg.
Paracetamol Tab. 500mg, Syr. 125mg/5ml, Inj. 150mg/ml
Ibuprofen Tab. 200, 400 mg, Susp. 100mg/5ml
Diclofenac Sodium Tab. 50 mg, Tab. 75 mg SR, Inj. 25mg/ml
3. ANTIALLERGIC AND DRUGS USED IN ANAPHYLAXIS
Chlorpheniramine Maleate Tab. 4mg
Pheniramine maleate Tab. 25, 50 mg, Syr. 15mg/5ml, Inj. 22.75 mg/ml
Dexamethasone Sodium phosphate Tab. 0.5mg, Inj. 4mg/ml
Hydrocortisone Sodium succinate Powder for Inj. 100mg/ml
Prednisolone Tab. 5mg; Syr. 5 mg/5ml
Epinephrine Hydrochloride Inj. 1mg/ml
Promethazine hydrochloride Inj. 25mg/ml in 1ml amp, Syr/elixir. 5mg/5ml
Cinnarizine Tab. 25 mg
Cetirizine Tab. 10 mg, Syr. 5 mg/5ml
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING
Anti snake venom (Polyvalent) Inj. Lyophilized
5. ANTI – EPILEPTIC DRUGS
Phenytoin sodium Tab. 50, 100 mg, Susp. 30 mg/5 ml
Phenobarbitone Syp 20 mg/5 ml, Tab. 30, 60 mg
Carbamazepine Tab. (uncoated) 100 mg,200 mg, Syr. 100 mg/5 ml
6. ANTI – INFECTIVE DRUGS
INTESTINAL ANTHELMINTICS
Mebendazole Tab. 100 mg, Powder for Susp. 100 mg./5 ml
Albendazole Tab. 400 mg, Susp. 200 mg/5 ml
Pyrantel pamoate Tab. 200, 250 mg, Powder for Susp. 50 mg/ml
ANTIFILARIALS
Diethylcarbamazine dihydrogen citrate Tab. 50 mg

* for restricted use only 9

 EML for dispensaries 2007

ANTIBACTERIALS
Benzathine Penicillin Powder for Inj.1.2, 2.4 MU/vial
Procaine Penicillin G Powder for Inj. 0.4MU/vial
Amoxicillin Cap.250, 500 mg, Susp. 125 mg/5 ml
Ampicillin Cap.250, 500 mg, Powder for Susp. 125 mg/5 ml
Cloxacillin Cap.250, 500 mg, Powder for Susp. 125 mg/5ml
Ciprofloxacin Tab. 250, 500mg
Norfloxacin Tab. 100mg dispersible; 200mg, 400mg coated
*Cephalexin Cap.125, 250, 500 mg, Syr. 125 mg/5 ml
Nalidixic acid Tab. 500 mg, Syr.300 mg./5 ml
Erythromycin (as Stearate) Tab.250 mg, Powder for Susp.125mg/5 ml
Roxithromycin Tab. 50, 150mg
Sulfamethoxazole + Trimethoprim Tab.400 mg+80 mg, Tab.800 mg+160 mg, Oral Susp.200 mg+40
mg in 5 ml
Doxycycline Cap.100 mg
ANTIFUNGAL DRUGS
Griseofulvin Tab.125, 250 mg
*Fluconazole Tab/Cap. 50, 150, 200 mg, Susp. 50mg/5ml
ANTI PROTOZOAL DRUGS
Chloroquine Phosphate Tab.250 mg, Syr. 50 mg/5 ml
Sulfadoxin + Pyrimethamine Tab.500 mg+25 mg
Tinidazole Tab. 300, 500mg
Metronidazole Tab.200, 400 mg, Susp. 200 mg/5 ml
Diloxanide furoate Tab.500 mg
7. DRUGS AFFECTING BLOOD
ANTIANAEMIC DRUGS
Ferrous Sulphate Tab. 200 mg (equivalent to 60 mg elemental iron)
Ferrous fumerate Drops 5 mg/ml
Folic acid Tab. 5 mg
Iron folic acid Tab Ferrous sulphate Exsiccated IP 333-335 mg (equivalent to
100 mg of elemental iron) + folic acid IP 0.5 mg; Tab. Ferrous
sulphate Exsiccated IP 67 mg (equivalent to 20 mg of elemental
iron) + folic acid IP 0.1 mg
DRUGS AFFECTING COAGULATION
*Tranexamic acid Tab.250,500 mg

* for restricted use only 10

 EML for dispensaries 2007

8. CARDIOVASCULAR DRUGS
ANTIANGINAL DRUGS
Atenolol Tab.50, 100 mg
Metoprolol Tab.50, 100 mg
Isosorbide dinitrate Tab.10 mg
Isosorbide mononitrate Tab. 10, 20 40 mg
ANTIHYPERTENSIVE DRUGS
Amlodipine Tab. 5 mg
Enalapril Tab. 2.5, 5 mg

Methyldopa§ Tab. 250 mg

§Methyldopa is listed for use in the management of pregnancy-induced hypertension only. Its use in the treatment
of essential hypertension is not recommended in view of the availability of better efficacy and safety of other
medicines.
9. DERMATOLOGICA DRUGS
ANTIFUNGAL DRUGS
Clotrimazole Cream 1% Powder 1% , Vaginal pessary 100 mg
Miconazole nitrate Oint. 2%
ANTI – INFECTIVE DRUGS
Silver sulfadiazine Cream 1 % 20g and 100g
Framycetin Cream 1 % 20g & 100g
Povidone iodine Sol. 5%, Ointment 5%, Vaginal pessary 200 mg
SCABICIDES AND PEDICULOCIDES
Permethrin Lotion1% 60 ml; Cream 5%
ANTI – INFLAMMAORY AND ANTIPRURITIC DRUGS
Betamethasone Valerate Cream, Ointment 0.1%
Calamine Lotion
10. DISINFECTANTS AND ANTISEPTICS
Chlorhexidine Soln. 0.2%
Tincture Benzoin Co.
Surgical Spirit Liquid
Hydrogen Peroxide Sol.6% w/v
Gentian violet Crystals for sol
Potassium Permanganate Crystals for sol.
11. DIURETICS
Hydrochlorothiazide Tab. 25, 50 mg
Frusemide Tab. 40 mg

* for restricted use only 11

 EML for dispensaries 2007

12. GASTROINTESTINAL DRUGS

ANTACIDS AND OTHER ANTI-ULCER DRUGS
Magnesium hydroxide + aluminium hydroxide Tab. (250 mg + 250 mg + 50 mg), Gel (250 mg + 250 mg + 50 +
activated dimethicone/simethicone mg/5 ml)
Omeprazole Cap. 20 mg
Ranitidine Tab. 150 mg, Inj. 50 mg/2 ml
ANTIEMETIC DRUGS
Metoclopramide Tab. 10 mg, Inj. 5 mg/ml amp.
Domperidone Tab. 10 mg, Susp. 1 mg/ml
ANTI-HAEMORRHOIDAL DRUGS
Beclomethasone dipropionate + Cream (0.025%, 0.1% + 2.5%)
Phenylephrine + Lignocaine

ANTISPASMODIC DRUGS
Dicyclomine Tab. 10 mg, Inj. 10 mg/ml
Dicyclomine + Activated dimethicone/simethicone Drops 10 mg+40 mg/ml
Hyoscine butylbromide Tab. 10 mg, Inj. 20 mg/ml
CATHARTIC DRUGS
Bisacodyl Tab. 5 mg
DRUGS USED IN DIARRHOEA
ORS (Low osmolarity: 245 mmol/L:
Sod chloride 2.6g/L, Trisodium citrate
dehydrate 2.9g/L, Pot. Chloride 1.5g/L,
Glucose anhydrous 13.5g/L)) Powder Sachet
Furazolidone Tab. 100 mg, Powder for Susp. 25mg/5ml
13. HORMONES, OTHER ENDOCRINE DRUGS AND CONTRACEPTIVES
PROGESTERONES
Norethisterone Tab.5 mg
Medroxyprogesterone acetate Tab. 2.5, 10mg
INSULIN AND OTHER ANTIDIABETIC DRUGS
Glibenclamide Tab.2.5, 5 mg
Metformin hydrochloride Tab.500, 850 mg
14. IMMUNOLOGICAL AGENTS
There should be no batch failure rate/substandard report from the authorized testing laboratory.
Tetanus toxoid Inj.
15. MUSCLE RELAXANT & ANTICHOLINESTERASE
Methocarbamol Tab.500 mg

* for restricted use only 12

 EML for dispensaries 2007

16. OXYTOCICS AND ANTIOXYTOCICS

Isoxsuprine Tab. 10 mg
Methylergometrine maleate Tab. 0.125 mg
17. PSYCOTHERAPEUTIC DRUGS
Imipramine Tab. 25, 75mg
Diazepam Tab. 5mg; Inj 5mg/ml
Alprazolam Tab.0.25mg, 0.5mg
18. DRUGS ACTING ON RESIRATORY SYSTEM
Etophylline+ theophylline Tab. 100mg (77+23mg); Tab. 150, 300mg SR;
Syr.(46.5+14mg/5ml), Inj.220mg/2 ml (169.4+50.6 mg)
Salbutamol Tab. 2mg, 4mg, Syr. 2mg/5ml, Solution for Nebulizer 5 mg/ml,
*Inhalation aerosol 100 mcg/dose in 200 doses
**Budesonide *Inhalation aerosol 100mcg/dose
** Metered dose inhalers are for restricted use and should be prescribed in diagnosed cases of chronic
asthma only for prevention and treatment.
ANTITUSSIVES
Noscapine Linctus 7mg/5 ml
Dextromethorphan Soln.30 mg/5ml
Bromhexine hydrochloride Syr.4mg/5 ml
19. SOLUTION CORRECTING WATER AND ELECTROLYTE
Dextrose Inj.5%,
Sodium chloride Inj.0.9%
20. VITAMINES AND MINERALS
Vitamin. A Soft gelatin Cap.25000IU, 50,000 IU
Multivitamin (Vitamin A 3000-5000 IU; Drops
Vitamin C 40-60 mg ; Vitamin D 400 IU;
Vitamin B1 1-2 mg; Vitamin B2 1-2 mg;
Vitamin B3 10-15mg;
Nicotinamide 10.5 -15mg;
Panthenol 1.5-3mg;
Vitamin B6 1-3 mg; Vitamin E 5.25- 8mg)
Vitamin D3 Granules 1 g sachet
Alphacalcidol Cap.0.25 mcg
Vitamin C Tab.100, 500 mg
Calcium carbonate Tab. 250, 500 mg as elemental calcium
Calcium carbonate+ Vitamin D3 Syr. 250 mg as elemental calcium+125 IU/5 ml
21. DENTAL PREPARATIONS
Tannic acid Gum paint10%
Choline Salicylate soln + Benzalkonium Gel (0.01% + 9% all w/v) 8.7% Soln. IP 0.01%
chloride soln + Lignocaine HCL IP w/w 2% w/w in flavored jelly base oral gel 30g/tube

* for restricted use only 13

 EML for dispensaries 2007

22. OPHTHALMOLOGICAL PREPARATIONS

ANTI-INFECTIVE AGENTS
Sulfacetamide Eye drops 20%
Ciprofloxacin Eye drops 0.3%, Eye oint.0.3%
Framycetin Eye drops 0.5%
ANTIINFLAMMATORY AGENTS
Ketorolac Eye drops 0.5%/5ml vial
23. ENT DRUGS
Gentamicin Ear drops (0.3% w/v)
Gentamicin + Betamethasone Ear drops (0.3% w/v + 0.1%)
Clotrimazole Ear drops 1%
Xylometazoline Nasal drops 0.1, 0.05%

Anti-leprosy, anti-tubercular, oral contraceptives and vaccines are not included in this list as they are
supplied to the dispensaries under various national health schemes.

* for restricted use only 14

 EML for dispensaries 2007

ABBREVIATIONS

Amp. Ampoule
Cap. Capsule
Inhal. Inhalation
MDI Metered dose inhaler
Inj. Injection
Linct. Linctus
Oint. Ointment
Susp. Suspension
Syr. Syrup
Liq. Liquid
Tab. Tablet
CR Controlled release
SR Slow release

* for restricted use only 15